Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMBASSADOR: Pembrolizumab vs Observation in Muscle-Invasive and Locally Advanced Urothelial Carcinoma
NCT03244384Phase 3Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Nov 2017
- Primary completion
- Jan 2027
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of pembrolizumab in urothelial carcinoma (UC), sponsored by National Cancer Institute. Primary endpoint: Overall Survival at 5 years. Started Nov 2017; status: active, not recruiting.
02
Drugs
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT03244384.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03244384.